Treatment Naïve

A5353 A Study to Evaluate Dolutegravir plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants

Q:            In treatment-naive participants, dual therapy with DTG plus 3TC is efficacious and well tolerated.

POP:        120 HIV treatment naïve men and women 18 years of age or older. HIV VL> 100,000

Med:        Dolutegravir 50mg daily and lamivudine 300mg daily

DUR:        52 weeks

CALL:      Becky Straub, RN 919-843-9975, bstraub@med.unc.edu